Skip to main content

Markit Announces CDS Index Licensing to SEFs

city-of-london-dragon-and-gherkin
Markit is based in London

As of October 2nd, the official first day of swaps trading under new Dodd-Frank rules, a quartet of facilities including Bloomberg, MarketAxess, Tera Exchange, and Tradeweb have been licensed to execute trades in the CDS indices, but all SEFs currently have the ability to do so for the same cost.

"Markit's CDX and iTraxx are among the most liquid in the CDS market, and we are pleased to be working with the SEF community to enable all market participants to trades our indices on the new trading

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: https://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

Register for free

Access two articles, our IMD and Waters Wraps, plus a member newsletter. Find out more.

All fields are mandatory unless otherwise highlighted.

Show password
Hide password

Market data costs defy cyclicality

Trading firms continue to grapple with escalating market data costs. Can innovative solutions and strategic approaches bring relief?

AI & data enablement: A looming reality or pipe dream?

Waters Wrap: The promise of AI and agents is massive, and real-world success stories are trickling out. But Anthony notes that firms still need to be hyper-focused on getting the data foundation correct before adding layers.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here